Bronchiectasis

6 trials 4 recruiting MedDRA PT
6 Registered trials
4 Recruiting
5 Unique sponsors
4 Unique IMPs
4 Commercial trials
Drug classes (ATC)
ATC code not specified 5
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 3 substances
Monoclonal antibody 1 substance
Phase II: 5 Phase IV: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase II

5 trials
  • Boehringer Ingelheim International GmbH Commercial
    BI 1291583
    2022-502835-21-00 6 countries 2024 n=17
    Ended
  • Boehringer Ingelheim International GmbH Commercial
    BI 1291583
    2023-503290-38-00 14 countries 2023 n=114
    Recruiting
  • GSK PLC Commercial
    GSK3862995B
    2025-522892-27-00 6 countries 2026 n=207
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    ITEPEKIMAB
    2023-508663-70-00 9 countries 2024 n=138
    Ended
  • Philipps-Universitaet Marburg Academic
    COLISTIMETHATE SODIUM
    2023-509277-22-00 1 country 2022 n=66
    Recruiting

Phase IV

1 trial
  • Hospital Universitari De Girona Doctor Josep Trueta Academic
    IMP not specified
    2024-511677-29-01 1 country 2024 n=57
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Boehringer Ingelheim International GmbH Commercial 2 Phase II 1
GSK PLC Commercial 1 Phase II 1
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II 0
Philipps-Universitaet Marburg Academic 1 Phase II 1
Hospital Universitari De Girona Doctor Josep Trueta Academic 1 Phase IV 1
New trials by year
2022
1
2023
1
2024
3
2026
1
← All indication landscapes